Skip to content

Comparison between two different routes of Furosemide administration in Patients with Pulmonary Edema

A Comparison between Intravenous Furosemide and Nebulized Furosemide in Controlling the Symptoms of the Patients with Pulmonary Edema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017030332853N1
Enrollment
85
Registered
2017-03-29
Start date
2017-05-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary edema. Acute pulmonary edema

Interventions

Intervention 1: In the intervention group the patients will receive nebulized furosemide at a dose of 1 mg furosemide for 20 minutes in 2 ml of sodium chloride 0.9%. Intervention 2: The control group
Treatment - Drugs
In the intervention group the patients will receive nebulized furosemide at a dose of 1 mg furosemide for 20 minutes in 2 ml of sodium chloride 0.9%
The control group the patients will receive intravenous furosemide at a dose of 1mg / kg

Sponsors

Ahvaz Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with shortness of breath during the past six hours, patients with clinical signs of pulmonary edema (tachypnea, increased lung function, use of accessory muscles, crackles, wheezes and gallop rhythm), and radiographically diagnosis of pulmonary edema. Exclusion criteria: Cardiogenic shock and blood pressure less than 90 mmHg, noncardiogenic pulmonary edema, myocardial infarction, severe heart valve disease, history of pulmonary obstructive disease, patients requiring intubation, cardiac arrhythmias, liver failure, cancer, sensitivity to Furosemide , patient’s dissatisfaction and pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Dyspnea severity. Timepoint: 15,30,60 and 120 minutes after treatment. Method of measurement: Dyspnea Scale criteria.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaye Shaabani

Ahvaz Jundishapur University of Medical Sciences

s.shaabani@ajums.ac.ir+98 61 3374 3009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026